Abstract:Spinal muscular atrophy (SMA) is caused by the loss or mutation of both copies of the survival motor neuron 1 (SMN1) gene. The related SMN2 gene is retained, but due to alternative splicing of exon 7, produces insufficient levels of the SMN protein. Here, we systematically characterize the pharmacokinetic and pharmacodynamics properties of the SMN splicing modifier SMN-C1. SMN-C1 is a low-molecular weight compound that promotes the inclusion of exon 7 and increases production of SMN protein in human cells and in two transgenic mouse models of SMA. Furthermore, increases in SMN protein levels in peripheral blood mononuclear cells and skin correlate with those in the central nervous system (CNS), indicating that a change of these levels in blood or skin can be used as a non-invasive surrogate to monitor increases of SMN protein levels in the CNS. Consistent with restored SMN function, SMN-C1 treatment increases the levels of spliceosomal and U7 small-nuclear RNAs and corrects RNA processing defects induced by SMN deficiency in the spinal cord of SMNΔ7 SMA mice. A 100% or greater increase in SMN protein in the CNS of SMNΔ7 SMA mice robustly improves the phenotype. Importantly, a ∼50% increase in SMN leads to long-term survival, but the SMA phenotype is only partially corrected, indicating that certain SMA disease manifestations may respond to treatment at lower doses. Overall, we provide important insights for the translation of pre-clinical data to the clinic and further therapeutic development of this series of molecules for SMA treatment.

Binding to SMN2 pre-mRNA-protein complex elicits specificity for small molecule splicing modifiers

Pharmacokinetics, pharmacodynamics, and efficacy of a small-molecule SMN2 splicing modifier in mouse models of spinal muscular atrophy

Diverse targets of SMN2-directed splicing-modulating small molecule therapeutics for spinal muscular atrophy

Antisense Masking of an Hnrnp A1/A2 Intronic Splicing Silencer Corrects SMN2 Splicing in Transgenic Mice

Discovery and Optimization of Small Molecule Splicing Modifiers of Survival Motor Neuron 2 as a Treatment for Spinal Muscular Atrophy

Specificity, synergy, and mechanisms of splice-modifying drugs

Enhancement of SMN2 Exon 7 Inclusion by Antisense Oligonucleotides Targeting the Exon.

Targeting RNA-Splicing for SMA Treatment

Identification of SRSF10 As a Regulator of SMN2 ISS-N1.

Structure of SRSF1 RRM1 bound to RNA reveals an unexpected bimodal mode of interaction and explains its involvement in SMN1 exon7 splicing

Improvement of SMN2 pre-mRNA processing mediated by exon-specific U1 small nuclear RNA

Synergistic Effect of an Antisense Oligonucleotide and Small Molecule on Splicing Correction of the Spinal Muscular Atrophy Gene

The diversity of splicing modifiers acting on A-1 bulged 5′-splice sites reveals rules for rational drug design

Characterization of the RNA recognition mode of hnRNP G extends its role in SMN2 splicing regulation

A splicing silencer in SMN2 intron 6 is critical in spinal muscular atrophy

A Small Molecule Antagonist of SMN Disrupts the Interaction Between SMN and RNAP II

Optimization of base editors for the functional correction of SMN2 as a treatment for spinal muscular atrophy

RNA-based drug discovery for spinal muscular atrophy: a story of small molecules and antisense oligonucleotides

Drug screening with human SMN2 reporter identifies SMN protein stabilizers to correct SMA pathology

A Splicing Silencer Insmn2intron 6 is Critical in Spinal Muscular Atrophy

Discovery, synthesis, and biological evaluation of novel SMN protein modulators